Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR‐mutated lung adenocarcinoma who, after 23‐month treatment with gefitinib, developed the EGFR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Liu, Yutao, Hao, Xuezhi, Hu, Xingsheng, Li, Junling, Wang, Yan, Wang, Hongyu, Xing, Puyuan, Li, Weihua, Ying, Jianming, Han, Xiaohong, Shi, Yuankai
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2018
Matèries:
Case Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5879057/
https://ncbi.nlm.nih.gov/pubmed/29411527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12596
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars